| Project/Area Number |
16590944
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | KYUSHU UNIVERSITY |
|---|
Principal Investigator |
MUTA Hiromi Kyushu University, Kyushu University Hospital, Research Associate, 大学病院, 助手 (40325478)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANI Kenzaburo Kyushu University, Medical Institute of Bioregulation, Professor, 生体防御医学研究所, 教授 (00183864)
HARADA Mamoru Kurume University, Kurume University Hospital, Associate Professor, 医学部, 助教授 (50260716)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2005: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 2004: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | Dendritic cell / Taylor made / Peptide |
|---|
| Research Abstract |
This study is designated to vaccinate patients intracutaneously with dendritic cells pulsed with maximum four newly established cancer specific peptides (Taylor made peptides) selected by peptide-specific cytotoxic T lymphocyte (CTL) precursor analysis by IFN-gamma productions and peptide-reactive IgG by an enzyme-linked immunosorbent assay (ELISA). The summary of research results is following.
Generation of GMP grade products in Cell Processing Facility.
We constructed specific facility for cell culture "Cell Processing Facility (CPF)", and test culture of the dendritic cells has been done in the CPF. Environmental measurement has been done by air sampler and particle counter during culture procedure, and all the results were satisfied with the environmental standards. Bacteria or fungus or mycoprasma are all negative in culture media. These results indicating GMP products can be generated in this facility.
Approval of the Protocol by Institutional Ethical Review Boards
This "Clinical study of cancer immunotherapy with dendritic cells pulsed with Taylor made peptides" is approved by Institutional Ethical Review Boards on January 22nd 2004.
Case conference
All the patients were refered to the case conference held by Clinical Research Center Kyushu University. Five out of 36 registered patients were enrolled to the study. Three patients were vaccinated with dendritic cells. Two cases were discontinued because of the worsening of the primary disease.
Patient Treatment
Three cases were vaccinated with 3x10^6 of dendritic cells. Local redness of the injection site was observed in all cases. Anti tumor effect was PD in all the cases according to the RECIST guideline. In one case, reduction of the tumor marker was observed. Immunological analysis is under investigation.
|
